Relapsed SCLC

Drug:
ABBV-706 is an antibody drug conjugate (ADC) consisting of an anti-seizure-related 6 homolog (SEZ6; PR-1744211)
targeting antibody conjugated to a potent inhibitor of topoisomerase 1 (Top1; A-1743332). SEZ6 is a
transmembrane protein that is overexpressed in most SCLCs.



• Diagnosis of histologically or cytologically confirmed R/R SCLC.
• Subjects must have progressed on prior systemic therapy, with CPI (if eligible) and prior tarlatamab, defined as:
a. In the 1L and 2L setting respectively, platinum-based chemotherapy (i.e., carboplatin or cisplatin and etoposide with CPI, if eligible for CPI) and 2L tarlatamab; or
b. In the 1L and 2L setting, platinum-based chemotherapy (i.e., carboplatin and etoposide with atezolizumab and lurbinectedin in combination with atezolizumab maintenance and 2L tarlatamab; or
c. In the 1L setting, platinum-based chemotherapy (i.e., carboplatin or cisplatin and etoposide with CPI, if eligible for CPI) in combination with tarlatamab in frontline induction and/or maintenance.
• Subjects must be considered suitable to receive SOC comparator (topotecan, lurbinectedin, or amrubicin).